These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16122403)

  • 41. The inhalers of the future? A review of dry powder devices on the market today.
    Smith IJ; Parry-Billings M
    Pulm Pharmacol Ther; 2003; 16(2):79-95. PubMed ID: 12670777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Propellant-driven metered-dose inhalers for pulmonary drug delivery.
    Smyth HD
    Expert Opin Drug Deliv; 2005 Jan; 2(1):53-74. PubMed ID: 16296735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. State of the art and new perspectives on dry powder inhalers.
    Terzano C; Colombo P
    Eur Rev Med Pharmacol Sci; 1999; 3(6):247-54. PubMed ID: 11261735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chlorofluorocarbon to hydrofluoroalkane formulations: an industry perspective.
    Atkins P
    J Allergy Clin Immunol; 1999 Dec; 104(6):S268-70. PubMed ID: 10588988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Principles of metered-dose inhaler design.
    Newman SP
    Respir Care; 2005 Sep; 50(9):1177-90. PubMed ID: 16122401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
    Wu L; Al-Haydari M; da Rocha SR
    Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler.
    Ganderton D; Lewis D; Davies R; Meakin B; Church T
    Respir Med; 2003 Nov; 97 Suppl D():S4-9. PubMed ID: 14753246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. History of aerosol therapy: liquid nebulization to MDIs to DPIs.
    Anderson PJ
    Respir Care; 2005 Sep; 50(9):1139-50. PubMed ID: 16122398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical aerosol propellant interference with infrared anaesthetic gas monitors.
    Levin PD; Levin D; Avidan A
    Br J Anaesth; 2004 Jun; 92(6):865-9. PubMed ID: 15121726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continuing patient care with metered-dose inhalers.
    Woodcock A
    J Aerosol Med; 1995; 8 Suppl 2():S5-10. PubMed ID: 10155357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of ozone-depleting substances; removal of essential-use designations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(63):17167-92. PubMed ID: 15806739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alcohol-based pressurised metered-dose inhalers for use in asthma: a descriptive study.
    Alrasbi M; Sheikh A
    Prim Care Respir J; 2008 Jun; 17(2):111-3. PubMed ID: 18338091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen.
    Buttini F; Glieca S; Sonvico F; Lewis DA
    Expert Opin Drug Deliv; 2023; 20(8):1131-1143. PubMed ID: 37767756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulite: a simple solution to a difficult problem.
    Lewis DA; Ganderton D; Meakin BJ; Brambilla G
    Respiration; 2005; 72 Suppl 1():3-5. PubMed ID: 15915006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of international environmental agreements in metered-dose inhaler technology changes.
    Forte R; Dibble C
    J Allergy Clin Immunol; 1999 Dec; 104(6):S217-20. PubMed ID: 10588977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Possible replacements for CFC-propelled metered-dose inhalers.
    Dalby RN
    Med Device Technol; 1991 May; 2(4):21-5. PubMed ID: 10149436
    [No Abstract]   [Full Text] [Related]  

  • 58. Phaseout of chlorofluorocarbons (CFCs) in metered-dose inhalers. Highlights of the Canadian initial transition strategy.
    D'Urzo AD; D'Urzo DK
    Can Fam Physician; 1999 Jun; 45():1544-6, 1556-7. PubMed ID: 10386220
    [No Abstract]   [Full Text] [Related]  

  • 59. Preparing for a change in metered-dose inhalers. National Asthma Education and Prevention Program CFC Phaseout Working Group.
    Minn Med; 1998 Feb; 81(2):26-7. PubMed ID: 9505495
    [No Abstract]   [Full Text] [Related]  

  • 60. The ester group: how hydrofluoroalkane-philic is it?
    Peguin RP; Wu L; da Rocha SR
    Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.